In this post-hoc analysis of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [16], we sought to provide further evidence for the potential efficacy and mechanism of action in relation to AD of once-weekly exenatide (EQW), a GLP-1 RA, while accounting for the effect of non-modifiable (age) and modifiable (previous cardiovascular events) risk factors. This evidence concerns the gene GCG and Alzheimer disease.